Insider transactions

EDGAR

Cross Country Healthcare, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
2 transactions, 5,000 shares
Sum of shares × price per share: 40,829.28
Open-market sales (code S)
1 transactions, 6,200 shares
Sum of shares × price per share: 60,146.2

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 59

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-21 Filed 2026-07-21Burns William J. Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)336,43813.25
4,457,803.5

Derived: shares × price per share. Exact value 4457803.50.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000694 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Burns William J. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)104,1570—104,157Direct (D) No
F3
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000694 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Burns William J. Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)104,15713.25
1,380,080.25

Derived: shares × price per share. Exact value 1380080.25.

0Direct (D) No
F1, F2, F3
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000694 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Allen Dwayne Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)31,28913.25
414,579.25

Derived: shares × price per share. Exact value 414579.25.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000688 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Veizaga Marvin Officer: Chief Accounting Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)31,48013.25
417,110

Derived: shares × price per share. Exact value 417110.00.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000698 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Veizaga Marvin Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)16,7970—16,797Direct (D) No
F3
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000698 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Veizaga Marvin Officer: Chief Accounting Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)16,79713.25
222,560.25

Derived: shares × price per share. Exact value 222560.25.

0Direct (D) No
F1, F2, F3
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000698 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Krug Marc S. Officer: Group President, Delivery
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)77,23213.25
1,023,324

Derived: shares × price per share. Exact value 1023324.00.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000696 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Krug Marc S. Officer: Group President, Delivery
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)47,1200—47,120Direct (D) No
F3
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000696 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Krug Marc S. Officer: Group President, Delivery
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)47,12013.25
624,340

Derived: shares × price per share. Exact value 624340.00.

0Direct (D) No
F1, F2, F3
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000696 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Clark Kevin Cronin Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)948,13313.25
12,562,762.25

Derived: shares × price per share. Exact value 12562762.25.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000693 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Clark Kevin Cronin Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)247,4160—247,416Direct (D) No
F3
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000693 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Clark Kevin Cronin Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)247,41613.25
3,278,262

Derived: shares × price per share. Exact value 3278262.00.

0Direct (D) No
F1, F2, F3
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000693 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Clark Kevin Cronin Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)3,96113.25
52,483.25

Derived: shares × price per share. Exact value 52483.25.

0Indirect (I) By SpouseNo
F1, F2, F4
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F4 Represents shares held by Mr. Clark's spouse. Mr. Clark disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Open filing 0001012975-26-000693 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Nevin Janice Elizabeth Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)48,61613.25
644,162

Derived: shares × price per share. Exact value 644162.00.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000692 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Hawkins Amiee Lin Officer: Chief Operating Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)43,95313.25
582,377.25

Derived: shares × price per share. Exact value 582377.25.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000697 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Hawkins Amiee Lin Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)27,8970—27,897Direct (D) No
F3
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000697 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Hawkins Amiee Lin Officer: Chief Operating Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)27,89713.25
369,635.25

Derived: shares × price per share. Exact value 369635.25.

0Direct (D) No
F1, F2, F3
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000697 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Bhamidipati Venkat Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)29,75913.25
394,306.75

Derived: shares × price per share. Exact value 394306.75.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000689 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Ball Susan E Officer: General Counsel and Secretary
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)241,77713.25
3,203,545.25

Derived: shares × price per share. Exact value 3203545.25.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000695 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Ball Susan E Officer: General Counsel and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)72,8720—72,872Direct (D) No
F3
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000695 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21Ball Susan E Officer: General Counsel and Secretary
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)72,87213.25
965,554

Derived: shares × price per share. Exact value 965554.00.

0Direct (D) No
F1, F2, F3
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F3 At the Effective Time, each performance-based restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested (at target levels) and cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award (at target) immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000695 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21CASH W LARRY Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)223,31213.25
2,958,884

Derived: shares × price per share. Exact value 2958884.00.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000690 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21FITZGERALD GALE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)114,33113.25
1,514,885.75

Derived: shares × price per share. Exact value 1514885.75.

0Direct (D) No
F1, F2
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Open filing 0001012975-26-000691 Read from the filing’s XML Dispute this row
2026-07-21 Filed 2026-07-21FITZGERALD GALE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)79,91813.25
1,058,913.5

Derived: shares × price per share. Exact value 1058913.50.

0Indirect (I) By family trustNo
F1, F2, F3
  • F1 Pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the Issuer), KL Criss Cross Intermediate, LLC, a Delaware limited liability company (Parent), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (Merger Sub), pursuant to which Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
  • F2 at the effective time of the Merger (the Effective Time), each (i) share of Issuer common stock (Common Stock) issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the Merger Consideration) and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
  • F3 These shares are held in a trust for the benefit of the reporting person. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Open filing 0001012975-26-000691 Read from the filing’s XML Dispute this row
2026-07-09 Filed 2026-07-10Veizaga Marvin Officer: Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)23613.21
3,117.56

Derived: shares × price per share. Exact value 3117.56.

31,480Direct (D) No
F1
  • F1 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on July 9, 2026.
Open filing 0001012975-26-000647 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Ball Susan E Officer: General Counsel and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)33,6440—245,480Direct (D) No
F1
  • F1 These restricted shares of common stock vest in three substantially equal installments. The installments will vest on March 31, 2027, March 31, 2028 and March 31, 2029.
Open filing 0001012975-26-000309 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Ball Susan E Officer: General Counsel and Secretary
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,6899.40
15,876.6

Derived: shares × price per share. Exact value 15876.60.

243,791Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000309 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Ball Susan E Officer: General Counsel and Secretary
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,0149.40
18,931.6

Derived: shares × price per share. Exact value 18931.60.

241,777Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000309 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Burns William J. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)47,8730—341,751Direct (D) No
F1
  • F1 These restricted shares of common stock vest in three substantially equal installments. The installments will vest on March 31, 2027, March 31, 2028 and March 31, 2029.
Open filing 0001012975-26-000310 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Burns William J. Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,4239.40
22,776.2

Derived: shares × price per share. Exact value 22776.20.

339,328Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000310 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Burns William J. Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,8909.40
27,166

Derived: shares × price per share. Exact value 27166.00.

336,438Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000310 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Veizaga Marvin Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)9,0430—32,654Direct (D) No
F1, F2
  • F1 These restricted shares of common stock vest in three substantially equal installments. The installments will vest on March 31, 2027, March 31, 2028 and March 31, 2029.
  • F2 Reflects an additional 4,471 shares of common stock that were inadvertently omitted from the Reporting Person's Form 3 filed on March 25, 2026.
Open filing 0001012975-26-000308 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Veizaga Marvin Officer: Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5019.40
4,709.4

Derived: shares × price per share. Exact value 4709.40.

32,153Direct (D) No
F3
  • F3 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000308 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Veizaga Marvin Officer: Chief Accounting Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)4379.40
4,107.8

Derived: shares × price per share. Exact value 4107.80.

31,716Direct (D) No
F3
  • F3 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000308 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Clark Kevin Cronin Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)138,9630—948,133Direct (D) No
F1
  • F1 These restricted shares of common stock vest in three substantially equal installments. The installments will vest on March 31, 2027, March 31, 2028 and March 31, 2029.
Open filing 0001012975-26-000311 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Hawkins Amiee Lin Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)15,9580—45,231Direct (D) No
F1
  • F1 These restricted shares of common stock vest in three substantially equal installments. The installments will vest on March 31, 2027, March 31, 2028 and March 31, 2029.
Open filing 0001012975-26-000312 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Hawkins Amiee Lin Officer: Chief Operating Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5839.40
5,480.2

Derived: shares × price per share. Exact value 5480.20.

44,648Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000312 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Hawkins Amiee Lin Officer: Chief Operating Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)6959.40
6,533

Derived: shares × price per share. Exact value 6533.00.

43,953Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000312 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Krug Marc S. Officer: Group President, Delivery
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)21,0240—79,694Direct (D) No
F1
  • F1 These restricted shares of common stock vest in three substantially equal installments. The installments will vest on March 31, 2027, March 31, 2028 and March 31, 2029.
Open filing 0001012975-26-000313 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Krug Marc S. Officer: Group President, Delivery
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,1239.40
10,556.2

Derived: shares × price per share. Exact value 10556.20.

78,571Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000313 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-04-02Krug Marc S. Officer: Group President, Delivery
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,3399.40
12,586.6

Derived: shares × price per share. Exact value 12586.60.

77,232Direct (D) No
F2
  • F2 These shares were withheld to satisfy tax withholding obligations for restricted stock which vested on March 31, 2026.
Open filing 0001012975-26-000313 Read from the filing’s XML Dispute this row
2026-03-11 Filed 2026-03-12McDonald Colin Patrick Officer: Chief Human Resources Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,2009.7010
60,146.2

Derived: shares × price per share. Exact value 60146.2000.

28,060Direct (D) No
F1
  • F1 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.70 to $9.72 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
Open filing 0001012975-26-000243 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22Allen Dwayne Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)18,6800—31,289Direct (D) No
F1
  • F1 These restricted shares of common stock (RSAs) will vest on December 18. The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.
Open filing 0001012975-25-000961 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22Krug Marc S. Officer: Group President, Delivery
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)23,8170—58,670Direct (D) No
F1
  • F1 These restricted shares of common stock (RSAs) vest in three substantially equal installments on each of December 18, 2026, March 31, 2027 and March 31, 2028. The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025. After the initial vesting date 12 months from the grant date, the remaining RSAs will vest on March 31 of the two subsequent years to coincide with the vesting dates of the Company's previously granted RSAs.
Open filing 0001012975-25-000956 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22Nevin Janice Elizabeth Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)18,6800—48,616Direct (D) No
F1
  • F1 These restricted shares of common stock (RSAs) will vest on December 18. The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.
Open filing 0001012975-25-000965 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22FITZGERALD GALE S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)18,6800—114,331Direct (D) No
F1
  • F1 These restricted shares of common stock (RSAs) will vest on December 18. The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.
Open filing 0001012975-25-000964 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22Noe Phillip Lyn Officer: Chief Information Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)12,8260—23,146Direct (D) No
F1
  • F1 These restricted shares of common stock (RSAs) vest in three substantially equal installments on each of December 18, 2026, March 31, 2027 and March 31, 2028. The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025. After the initial vesting date 12 months from the grant date, the remaining RSAs will vest on March 31 of the two subsequent years to coincide with the vesting dates of the Company's previously granted RSAs.
Open filing 0001012975-25-000959 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22Bhamidipati Venkat Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)18,6800—29,759Direct (D) No
F1
  • F1 These restricted shares of common stock (RSAs) will vest on December 18. The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.
Open filing 0001012975-25-000962 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22Ball Susan E Officer: General Counsel and Secretary
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)35,8040—211,836Direct (D) No
F1
  • F1 These restricted shares of common stock (RSAs) vest in three substantially equal installments on each of December 18, 2026, March 31, 2027 and March 31, 2028. The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025. After the initial vesting date 12 months from the grant date, the remaining RSAs will vest on March 31 of the two subsequent years to coincide with the vesting dates of the Company's previously granted RSAs.
Open filing 0001012975-25-000952 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
Allen Dwayne DirectorCommon Stock 0D As of 2026-07-21 Open filing 4
Ball Susan E Officer: General Counsel and SecretaryCommon Stock 0D As of 2026-07-21 Open filing 4
Bhamidipati Venkat DirectorCommon Stock 0D As of 2026-07-21 Open filing 4
Burns William J. Officer: Chief Financial OfficerCommon Stock 0D As of 2026-07-21 Open filing 4
CASH W LARRY DirectorCommon Stock 0D As of 2026-07-21 Open filing 4
Clark Kevin Cronin Director · Officer: Chief Executive OfficerCommon Stock 3,961I By SpouseAs of 2026-04-02 Open filing 4
Clark Kevin Cronin Director · Officer: Chief Executive OfficerCommon Stock 0D As of 2026-07-21 Open filing 4
Clark Kevin Cronin Director · Officer: Chief Executive OfficerCommon Stock 0I By SpouseAs of 2026-07-21 Open filing 4
FITZGERALD GALE S DirectorCommon Stock 79,918I By family trustAs of 2025-12-22 Open filing 4
FITZGERALD GALE S DirectorCommon Stock 0D As of 2026-07-21 Open filing 4
FITZGERALD GALE S DirectorCommon Stock 0I By family trustAs of 2026-07-21 Open filing 4
Grieco Cynthia Ann Officer: VP, Corporate TreasurerCommon Stock 17,627D As of 2025-12-18 Open filing 4
Hawkins Amiee Lin Officer: Chief Solutions Ops. Ofcr.Common Stock 29,273D As of 2026-02-18 Open filing 3
Hawkins Amiee Lin Officer: Chief Operating OfficerCommon Stock 0D As of 2026-07-21 Open filing 4
Krug Marc S. Officer: Group President, DeliveryCommon Stock 0D As of 2026-07-21 Open filing 4
Martins John Anthony Director · Officer: President, CEOCommon Stock 150,935D As of 2025-03-31 Open filing 4
McDonald Colin Patrick Officer: Chief Human Resources OfficerCommon Stock 28,060D As of 2026-03-11 Open filing 4
Mote Karen Officer: Pres., Cross Country LocumsCommon Stock 32,407D As of 2025-12-18 Open filing 4
Nevin Janice Elizabeth DirectorCommon Stock 0D As of 2026-07-21 Open filing 4
Noe Phillip Lyn Officer: Chief Information OfficerCommon Stock 23,146D As of 2025-12-18 Open filing 4
Redd James V. III Officer: Chief Accounting OfficerCommon Stock 31,110D As of 2025-12-18 Open filing 4
Veizaga Marvin Officer: Chief Accounting OfficerCommon Stock 19,140D As of 2026-03-25 Open filing 3
Veizaga Marvin Officer: Chief Accounting OfficerCommon Stock 0D As of 2026-07-21 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–3 of 3

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Allworth Financial LP 223 SH2,946 dollarsUnchanged Prior quarter: 223Open filing 0001140361-26-042358 Filed 2026-11-06 Dispute this row
GLENMEDE TRUST CO NA 175 SH2,485 dollarsNot in the prior quarter’s filings read Open filing 0001398344-26-020129 Filed 2026-11-16 Dispute this row
IFP Advisors, Inc Partly reported under another manager7 SH93 dollarsHigher by 1 Prior quarter: 6Open filing 0001641866-26-000005 Filed 2026-10-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • BlackRock, Inc. 2,750,102 SH
  • DIMENSIONAL FUND ADVISORS LP 1,576,825 SH
  • First Eagle Investment Management, LLC 1,494,562 SH
  • FIL Ltd 1,292,260 SH
  • VANGUARD CAPITAL MANAGEMENT LLC 1,277,686 SH
  • GLAZER CAPITAL, LLC 1,111,727 SH
  • Sio Capital Management, LLC 1,098,393 SH
  • ODDO BHF ASSET MANAGEMENT SAS 989,574 SH
  • AMERICAN CENTURY COMPANIES INC 939,132 SH
  • Dana Investment Advisors, Inc. 918,344 SH
  • MILLENNIUM MANAGEMENT LLC 912,378 SH
  • GABELLI FUNDS LLC 870,114 SH
  • GEODE CAPITAL MANAGEMENT, LLC 804,289 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 786,525 SH
  • Sixth Street Partners Management Company, L.P. 786,525 SH
  • Quinn Opportunity Partners LLC 775,306 SH
  • STATE STREET CORP 670,695 SH
  • NEXPOINT ASSET MANAGEMENT, L.P. 656,630 SH
  • FMR LLC 492,648 SH
  • GABELLI Co INVESTMENT ADVISERS, INC. 479,988 SH
  • Aristotle Capital Boston, LLC 447,442 SH
  • LMR Partners LLP 368,045 SH
  • Russell Investments Group, Ltd. 365,939 SH
  • Prescott Group Capital Management, L.L.C. 347,818 SH
  • Walleye Capital LLC 336,034 SH
  • Allianz Asset Management GmbH 330,139 SH
  • Groupe la Francaise 324,000 SH
  • GOLDMAN SACHS GROUP INC 293,986 SH
  • SYSTEMATIC FINANCIAL MANAGEMENT LP 292,573 SH
  • VANGUARD PORTFOLIO MANAGEMENT LLC 292,375 SH
  • Sagefield Capital LP 285,025 SH
  • NORTHERN TRUST CORP 282,530 SH
  • MORGAN STANLEY 278,378 SH
  • Polar Asset Management Partners Inc. 272,495 SH
  • ALLIANCEBERNSTEIN L.P. 259,193 SH
  • Qube Research Technologies Ltd 252,575 SH
  • JANE STREET GROUP, LLC 251,002 SH
  • BANK OF AMERICA CORP /DE/ 233,748 SH
  • Maven Securities LTD 218,560 SH
  • CREDIT INDUSTRIEL ET COMMERCIAL 216,700 SH
  • VANGUARD FIDUCIARY TRUST CO 201,143 SH
  • UBS Group AG 169,558 SH
  • KESTREL INVESTMENT MANAGEMENT CORP 167,100 SH
  • OXFORD ASSET MANAGEMENT LLP 159,066 SH
  • RENAISSANCE TECHNOLOGIES LLC 152,683 SH
  • Nuveen, LLC 151,447 SH
  • WOLVERINE ASSET MANAGEMENT LLC 119,511 SH
  • Bank of New York Mellon Corp 117,351 SH
  • PARADIGM CAPITAL MANAGEMENT INC/NY 107,700 SH
  • Pacer Advisors, Inc. 106,868 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Institutional ownership reported on Form 13F

No percent is shown: the cover-page share count is not available for this company.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 33984058,935
2026-06-30 15311,925,71930,243,7609,178
2026-03-31 1538,448,66928,422,4529,173
2025-12-31 1487,972,82026,079,1419,222
2025-09-30 1709,469,50431,994,0938,469
2025-06-30 1638,720,94731,567,1288,516
2025-03-31 1639,087,56933,059,2928,518
2024-12-31 1769,119,90431,788,8898,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Boston Partners Common Stock0009/30/2026 Filed 2026-11-06SCHEDULE 13G/AAmendment 1Open filing 0001386060-26-000053 Dispute this row
Boston Partners Common Stock7.852,538,48103/31/2026 Filed 2026-05-14SCHEDULE 13GOpen filing 0001386060-26-000029 Dispute this row
Dimensional Fund Advisors LP Common Stock5.01,609,925.0003/31/2026 Filed 2026-04-09SCHEDULE 13G/AAmendment 1Open filing 0000354204-26-000551 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 9Open filing 0000102909-26-001048 Dispute this row
AllianceBernstein L.P. Common Stock0.131,215.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001109448-26-000072 Dispute this row
Magnetar Financial LLC Common Stock, par value $0.0001 per share4.981,631,864.0012/08/2025 Filed 2025-12-10SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-119881 Dispute this row
Magnetar Capital Partners LP Common Stock, par value $0.0001 per share4.981,631,864.0012/08/2025 Filed 2025-12-10SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-119881 Dispute this row
Supernova Management LLC Common Stock, par value $0.0001 per share4.981,631,864.0012/08/2025 Filed 2025-12-10SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-119881 Dispute this row
David J. Snyderman Common Stock, par value $0.0001 per share4.981,631,864.0012/08/2025 Filed 2025-12-10SCHEDULE 13D/AAmendment 3Open filing 0001104659-25-119881 Dispute this row
Magnetar Financial LLC Common Stock, par value $0.0001 per share5.541,815,542.0012/04/2025 Filed 2025-12-08SCHEDULE 13D/AAmendment 2Open filing 0001104659-25-119331 Dispute this row
Magnetar Capital Partners LP Common Stock, par value $0.0001 per share5.541,815,542.0012/04/2025 Filed 2025-12-08SCHEDULE 13D/AAmendment 2Open filing 0001104659-25-119331 Dispute this row
Supernova Management LLC Common Stock, par value $0.0001 per share5.541,815,542.0012/04/2025 Filed 2025-12-08SCHEDULE 13D/AAmendment 2Open filing 0001104659-25-119331 Dispute this row
David J. Snyderman Common Stock, par value $0.0001 per share5.541,815,542.0012/04/2025 Filed 2025-12-08SCHEDULE 13D/AAmendment 2Open filing 0001104659-25-119331 Dispute this row
AllianceBernstein L.P. Common Stock5.91,930,721.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001109448-25-000139 Dispute this row
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.0001 per share3.91,271,620.8909/30/2025 Filed 2025-11-12SCHEDULE 13G/AAmendment 2Open filing 0000886982-25-001453 Dispute this row
GOLDMAN SACHS CO. LLC Common Stock, par value $0.0001 per share3.91,271,620.8909/30/2025 Filed 2025-11-12SCHEDULE 13G/AAmendment 2Open filing 0000886982-25-001453 Dispute this row
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.0001 per share5.81,887,473.5706/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 1Open filing 0000769993-25-000450 Dispute this row
GOLDMAN SACHS CO. LLC Common Stock, par value $0.0001 per share5.81,887,473.5706/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 1Open filing 0000769993-25-000450 Dispute this row
BlackRock, Inc. Common Stock7.52,468,42406/30/2025 Filed 2025-07-16SCHEDULE 13G/AAmendment 5Open filing 0002052113-25-002543 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,817,351 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015218,057
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Cross Country Healthcare, Inc.